DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Study of Nasonex® for the Treatment of Nasal Polyps in Pediatric Subjects Between Ages of 6 and Less Than 18 Years Old (P04292)

Information source: Merck Sharp & Dohme Corp.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Nasal Polyps

Intervention: Mometasone Furoate Nasal Spray (MFNS) (Drug); Placebo nasal spray (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Merck Sharp & Dohme Corp.

Summary

The purpose of this study is to evaluate the safety and efficacy of Nasonex® (Mometasone Furoate Nasal Spray(MFNS)) in the treatment of nasal polyps in pediatric subjects between the ages of 6 and less than 18 years old. Safety will be the primary focus of this study.

Clinical Details

Official title: Study of Nasonex® for the Treatment of Nasal Polyps in Pediatric Subjects Between Ages of 6 and Less Than 18 Years Old

Study design: Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: Change From Baseline 24-hour Urinary Free Cortisol Level

Secondary outcome: Change From Baseline 24-hour Urinary Free Cortisol Level Corrected for Creatinine

Eligibility

Minimum age: 6 Years. Maximum age: 17 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- A subject must be 6 to <18 years of age, of either sex, and of any race.

- A subject must have a diagnosis of bilateral nasal polyps.

- A subject must have a minimum nasal congestion/obstruction

- An asthmatic subject may be included.

- A subject's clinical laboratory tests (hematology, blood chemistry, and urinalysis)

must be within normal limits or clinically acceptable to the investigator/sponsor.

- The subject and parent/guardian must be willing to give written informed consent, and

the subject must be able to adhere to dose and visit schedules.

- A female subject of child-bearing potential who is sexually active must have been

using a medically accepted method of contraception prior to Screening and must continue using it while receiving protocol-specified medication. If a pre-menarche female subject begins menstruating during the study, a serum pregnancy test must be done at the next visit Exclusion Criteria:

- A subject with antrochoanal polyps.

- A subject with cystic fibrosis.

- A subject with acute sinusitis, concurrent upper respiratory tract infection, or who

had an upper respiratory tract infection within 2 weeks prior to the Screening Visit.

- A subject with any clinically significant condition or situation, other than the

condition being studied that, in the opinion of the investigator, would interfere with the study evaluations or optimal participation in the study.

- A subject who is immunocompromised.

- A subject with ongoing rhinitis medicamentosa.

- A subject with Churg Strauss syndrome.

- A subject with dyskinetic ciliary syndromes, eg, Young's syndrome (sinopulmonary

infections and obstructive azoospermia) or Kartagener's syndrome (immotile cilia).

- A subject with any clinically significant pretreatment laboratory, vital sign, or ECG

abnormality.

- A subject with allergy/sensitivity to aspirin, corticosteroids, or study drug or its

excipients.

- A subject who has not observed the medication washout times outlined in the protocol

prior to the Screening Visit.

- A female subject who is breast-feeding, pregnant, or intends to become pregnant.

- A subject who has used any investigational drug within 30 days of Screening.

- A subject who is part of the staff personnel directly involved with this study.

Locations and Contacts

Additional Information

Starting date: July 2006
Last updated: May 27, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017